Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Davidson Capital Management Inc.

Davidson Capital Management Inc. raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,420 shares of the pharmaceutical company’s stock after buying an additional 524 shares during the quarter. Vertex Pharmaceuticals accounts for about 1.0% of Davidson Capital Management Inc.’s holdings, making the stock its 10th biggest position. Davidson Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $3,597,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mascagni Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth $31,000. Truvestments Capital LLC grew its stake in Vertex Pharmaceuticals by 30.3% in the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after purchasing an additional 23 shares in the last quarter. Mpwm Advisory Solutions LLC acquired a new position in Vertex Pharmaceuticals in the 4th quarter worth about $40,000. Midwest Capital Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $41,000. Finally, Minot DeBlois Advisors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth about $44,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX opened at $448.40 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a fifty day moving average price of $460.63 and a 200 day moving average price of $459.78. The stock has a market cap of $115.15 billion, a P/E ratio of -114.39 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the previous year, the firm posted $4.76 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on VRTX shares. Morgan Stanley boosted their price target on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 6th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Wolfe Research lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, May 7th. Scotiabank reduced their price objective on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a “sector perform” rating for the company in a research note on Tuesday, May 6th. Finally, Erste Group Bank cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, May 23rd. Fourteen analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $513.32.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.